Dr Jaffer Ajani speaks to ecancer about the efficacy of tislelizumab in oesophageal cancer after systemic therapy.
Initially, he talks about the background of the study. Dr Ajani then discusses the methodology and results. He explains that tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to chemotherapy in advanced or metastatic oesophageal squamous cell carcinoma after prior systemic therapy.
Additional Phase II data presented at ASCO showed tislelizumab demonstrated durable anti-tumour activity in patients with microsatellite instability-high, or mismatch-repair-deficient, solid tumours. In the end, he talks about the toxicity profile of the drug and the future impact of these results.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.